Yu, Jian

Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 2,328

Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7

Wang, P., Nair, M. S., Liu, L., Iketani, S., Luo, Y., Guo, Y., Wang, M., Yu, J., Zhang, B., Kwong, P. D., et al. (2021) · Nature

SARS-CoV-2 and COVID-19 ResearchAnimal Virus Infections Studies

Cited by 2,312

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike

Liu, L., Wang, P., Nair, M. S., Yu, J., Rapp, M., Wang, Q., Luo, Y., Chan, J. F.-W., Sahi, V., Figueroa, A., et al. (2020) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 1,349

Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2

Liu, L., Iketani, S., Guo, Y., Chan, J. F.-W., Wang, M., Liu, L., Luo, Y., Chu, H., Huang, Y., Nair, M. S., et al. (2022) · Nature

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 1,290

Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants

Wang, Q., Iketani, S., Li, Z., Liu, L., Guo, Y., Huang, Y., Bowen, A. D., Liu, M., Wang, M., Yu, J., et al. (2023) · Cell

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 912

Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization

Wang, P., Casner, R. G., Nair, M. S., Wang, M., Yu, J., Cerutti, G., Liu, L., Kwong, P. D., Huang, Y., Shapiro, L., et al. (2021) · Cell Host & Microbe

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 636

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-terminal domain target a single supersite

Cerutti, G., Guo, Y., Zhou, T., Gorman, J., Lee, M., Rapp, M., Reddem, E. R., Yu, J., Bahna, F., Bimela, J., et al. (2021) · Cell Host & Microbe

SARS-CoV-2 and COVID-19 Researchvaccines and immunoinformatics approaches

Cited by 519

SARS-CoV-2 neutralizing antibody responses are more robust in patients with severe disease

Wang, P., Liu, L., Nair, M. S., Yin, M. T., Luo, Y., Wang, Q., Yuan, T., Mori, K., Solis, A. G., Yamashita, M., et al. (2020) · Emerging Microbes & Infections

SARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research Studies

Cited by 122

Optimizing a Human Monoclonal Antibody for Better Neutralization of SARS-CoV-2

Wang, Q., Guo, Y., Casner, R. G., Yu, J., Nair, M. S., Ho, J., Reddem, E. R., Mellis, I. A., Wu, M., Tzang, C. C., et al. (2024) · Nature Communications

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 15

Optimizing a human monoclonal antibody for better neutralization of SARS-CoV-2

Wang, Q., Guo, Y., Casner, R. G., Yu, J., Nair, M. S., Ho, J., Reddem, E. R., Mellis, I. A., Wu, M., Tzang, C.-C., et al. (2025) · Nature Communications

SARS-CoV-2 and COVID-19 ResearchMonoclonal and Polyclonal Antibodies Research

Cited by 15